Researchers home in on mutation profiles of clear cell endometrial cancer

May 9, 2017
Endometrial cancer is the most commonly diagnosed gynecological cancer. Women with clear cell endometrial cancer, a rare type of endometrial cancer, generally have poorer clinical outcomes. Credit: Darryl Leja, NHGRI

In the largest genomics study of clear cell endometrial cancer (CCEC) tumors to date, National Human Genome Research Institute (NHGRI) researchers and their collaborators have identified mutations in the TAF1 gene. They've also demonstrated that the mutation profiles of CCEC tumors are sometimes similar to other types of uterine cancer, namely serous endometrial cancers or endometrioid endometrial cancers. The study was published May 9, 2017, in the journal Cancer.

Endometrial is the most commonly diagnosed gynecological cancer with more than 8,000 American women and 76,000 women worldwide dying from it every year. Fortunately, the most common type of endometrial cancer, endometrioid endometrial cancer, tends to diagnosed early and generally responds well to treatment; the five-year relative survival rate was reported as 91 percent in one study. However, women with CCEC or serous endometrial cancer, both rare types of endometrial cancer, generally have poorer clinical outcomes: One study reported that women with CCEC had a five-year relative survival rate of 65 percent, and women with serous endometrial cancer had a 45 percent five-year relative survival rate.

"Genomic that contribute to clear cell endometrial cancer can vary from one patient to another," said Daphne W. Bell, Ph.D., senior author and senior investigator in NHGRI's Cancer Genetics and Comparative Genomics Branch. "Because the cancer is often diagnosed after it has spread beyond the uterus, the mortality rate is unacceptably high. We're trying to build a knowledge base to decipher the fundamental genomic changes that drive these cancers." Dr. Bell and her team specialize in basic research aimed at identifying genes that are mutated (changed) in the tumors of with clinically aggressive forms of endometrial cancer.

Dr. Bell and her team isolated DNA from tumor cells and from normal cells from patients with CCEC. Their goal was to identify genetic mutations in CCEC tumor cells that are absent from normal . The team sequenced the exome, the building blocks (nucleotides) in the protein-coding regions of the tumor and normal DNA from 16 CCEC patients, and found mutations in 222 genes in the tumors. The team narrowed this list of 222 genes to 22 "genes-of-interest" that represented genes mutated in more than one CCEC patient, genes previously implicated in CCEC, and/or genes that are mutated in clear cell ovarian cancer. The team further searched for mutations in these 22 genes-of-interest in DNA from another 47 CCEC patients. Their results defined the frequency of mutation of the genes previously implicated in CCEC (TP53, PPP2R1A, PIK3R1, SPOP, PIK3CA, ARID1A and FBXW7) across the largest group of CCEC patients.

They also uncovered mutations in the TAF1 gene, a gene that had not been previously implicated in CCEC. TAF1 encodes part of a transcription factor complex, which regulates the expression of other throughout the genome. In addition, the researchers looked at patterns of gene mutations in tumors from CCEC patients and found that a substantial number of CCECs resembled serous endometrial cancer or endometrioid endometrial cancer.

The findings shed new light on the underlying genomic changes that are likely to be important in driving the development of CCEC, a rare but clinically aggressive form of .

Explore further: Researchers identify novel genes that may drive rare, aggressive form of uterine cancer

Related Stories

Researchers identify novel genes that may drive rare, aggressive form of uterine cancer

October 28, 2012
Researchers have identified several genes that are linked to one of the most lethal forms of uterine cancer, serous endometrial cancer. The researchers describe how three of the genes found in the study are frequently altered ...

Endometrial cancer driver mutations detectable in uterine lavage fluid

December 27, 2016
Mutations that have been linked to endometrial cancer can be found in the uterine lavage fluid of pre- and post-menopausal women both with and without detectable cancer, according to a study published in PLOS Medicine by ...

Findings support use of less invasive hysterectomy for early-stage endometrial cancer

March 28, 2017
Researchers found similar rates of disease-free survival and no difference in overall survival among women who received a laparoscopic or abdominal total hysterectomy for stage I endometrial cancer, according to a study published ...

Researchers find genes behind aggressive ovarian and endometrial cancers

October 11, 2016
In a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments.

Genes behind aggressive endometrial cancer found

January 28, 2013
In a major breakthrough for uterine serous carcinoma (USC)—a chemo-resistant, aggressive form of endometrial cancer, Yale researchers have defined the genetic landscape of USC tumors, findings that point to new treatment ...

Vaginal microbes point toward early detection and screening for endometrial cancer

January 5, 2017
Endometrial cancer triggers remain elusive, despite continued research. But given the typical inflammatory profile in these cases, microbes in the uterine environment are suspected to play a role in the development of this ...

Recommended for you

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

Scientists discover possible master switch for programming cancer immunotherapy

December 11, 2017
During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.